NEW YORK, Dec. 01, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) between March 25, 2016 and July 13, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Forman v. Meridian Bioscience, et al. (Case No. 1:17-cv-00774-SJD) in the USDC for the Southern District of Ohio. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/meridian-bioscience-inc-2?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that its subsidiary, Magellan Diagnostics, Inc. manufactured lead testing systems that provide inaccurate results.
On March 24, 2016, Meridian completed its acquisition of Magellan Biosciences, Inc. and its subsidiary Magellan Diagnostics, Inc. On May 17, 2017, the U.S. Food and Drug Administration and Centers for Disease Control and Prevention issued a press release “warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results…” Then on July 13, 2017, the FDA issued a statement that as part of an “aggressive investigation” the FDA had inspected Magellan Diagnostics’ facility and issued a report including “several inspectional observations that may be violations of federal law.”
If you suffered a loss in Meridian Bioscience you have until January 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



